ethyl (3S,4S)-3-phenylpiperidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl (3S,4S)-3-phenylpiperidine-4-carboxylate
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: RPMFBTVTRSNKTD-QWHCGFSZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100197697A1

  公开（公告）日：2010-08-05

  The present invention relates to a compounds of formula I wherein A, Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下结构的化合物I，其中A、Ar1、Ar2、R1、R2、R3、R4、R5、R6、m、n、o、p、s、t和u如本文所定义，或者与其药效活性盐、外消旋体混合物、对映体、光学异构体或其互变异构体有关。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• PIPERIDINE DERIVATIVE OR SALT THEREOF
  申请人：Hachiya Shunichiro

  公开号：US20100029687A1

  公开（公告）日：2010-02-04

  [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  【问题】提供一种化合物，可用于治疗钙感受受体（CaSR）参与的疾病，特别是甲状旁腺功能亢进症。【解决方法】发现一种新的哌啶衍生物，其特征在于3位和4位中的一个位置被取代为含有芳基烷基等基团的氨甲基基团，另一个位置被取代为芳基、杂环芳基等，或其盐，具有出色的CaSR激动调节作用，并且具有出色的选择性，具有可能引起药物相互作用的CYP2D6抑制作用。基于以上发现，这种新的哌啶衍生物可用作治疗CaSR参与的疾病（甲状旁腺功能亢进症、肾性骨营养不良、高钙血症等）的治疗剂。
• Piperidine derivatives as nk3 receptor antagonists
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2391615A1

  公开（公告）日：2011-12-07
• US8153658B2
  申请人：——

  公开号：US8153658B2

  公开（公告）日：2012-04-10
• US8324248B2
  申请人：——

  公开号：US8324248B2

  公开（公告）日：2012-12-04